CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
67 hedge funds and large institutions have $59.6M invested in CASI Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
14% more funds holding
Funds holding: 59 → 67 (+8)
4% more capital invested
Capital invested by funds: $57.2M → $59.6M (+$2.42M)
0.93% more ownership
Funds ownership: 2.27% → 3.2% (+0.93%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$13M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$12.4M |
| 3 |
Millennium Management
New York
|
+$1.21M |
| 4 |
Renaissance Technologies
New York
|
+$1.08M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$942K |
Top Sellers
CASI Hedge Fund Activity: Q3 2020 in Review
67 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2020, worth a combined $59.6M — up 4.2% from $57.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CASI positions and 5 closed out — a net gain of 8 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $13M. The largest seller was Wellington Shields & Co, cutting an estimated $200K.
- 67 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2020, up from 59 in Q2 2020.
- Funds reported $59.6M of CASI Pharmaceuticals stock for Q3 2020, up 4.2% quarter-over-quarter.
- 13 funds opened new CASI Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of +8 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2020 was Federated Hermes, an estimated $13M added.
- The largest CASI Pharmaceuticals seller in Q3 2020 was Wellington Shields & Co, an estimated $200K sold.
Based on aggregated 13F filings for Q3 2020.